** Shares of drug developer Lexicon Pharmaceuticals LXRX.O jump 108% to 72 cents premarket
** LXRX says it has entered into an agreement with Novo Nordisk NOVOb.CO to license its non-incretin based experimental drug for obesity and associated metabolic disorders
** Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory and sales milestone payments
** Novo Nordisk will hold an exclusive, worldwide license to develop, manufacture and commercialize the drug candidate, LX9851
** LXRX is eligible to receive tiered royalties on net sales of LX9851
** Up to last close, LXRX stock down 84% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。